drug
Arexvy
Marketedupdated 6mo agoby GlaxoSmithKline Biopharmaceuticals inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Arexvy
- phase2Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
- phase1A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
- phase1First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
- phase1Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
- phase2RSV Vaccination in Immunocompromised Patients.
News(3)
- GSK vaccine sales miss expectations amid falling demand from adultsWith pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.biospace · 1d ago
- GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentumThe layoffs across GSK’s Belgium sites come on the heels of the pharma’s planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.biospace · 15d ago
- GSK lays off 650 staffers amid closure of German vaccine manufacturing siteGSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid the pharma’s recent $2.5 billion savings campaign.biospace · 1mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that